BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 26053097)

  • 1. C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia.
    Hughes JM; Legnini I; Salvatori B; Masciarelli S; Marchioni M; Fazi F; Morlando M; Bozzoni I; Fatica A
    Oncotarget; 2015 Jul; 6(21):18534-44. PubMed ID: 26053097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of long non-coding RNA urothelial carcinoma associated 1 by CCAAT/enhancer binding protein α contributes to bladder cancer cell growth and reduced apoptosis.
    Xue M; Li X; Wu W; Zhang S; Wu S; Li Z; Chen W
    Oncol Rep; 2014 May; 31(5):1993-2000. PubMed ID: 24648007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
    Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
    J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML.
    Pulikkan JA; Dengler V; Peer Zada AA; Kawasaki A; Geletu M; Pasalic Z; Bohlander SK; Ryo A; Tenen DG; Behre G
    Leukemia; 2010 May; 24(5):914-23. PubMed ID: 20376080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
    Hickey CJ; Schwind S; Radomska HS; Dorrance AM; Santhanam R; Mishra A; Wu YZ; Alachkar H; Maharry K; Nicolet D; Mrózek K; Walker A; Eiring AM; Whitman SP; Becker H; Perrotti D; Wu LC; Zhao X; Fehniger TA; Vij R; Byrd JC; Blum W; Lee LJ; Caligiuri MA; Bloomfield CD; Garzon R; Marcucci G
    Blood; 2013 Jan; 121(1):159-69. PubMed ID: 23100311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
    Schmidt L; Heyes E; Scheiblecker L; Eder T; Volpe G; Frampton J; Nerlov C; Valent P; Grembecka J; Grebien F
    Leukemia; 2019 Jul; 33(7):1608-1619. PubMed ID: 30679799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A C-terminal mutant of CCAAT-enhancer-binding protein α (C/EBPα-Cm) downregulates Csf1r, a potent accelerator in the progression of acute myeloid leukemia with C/EBPα-Cm.
    Togami K; Kitaura J; Uchida T; Inoue D; Nishimura K; Kawabata KC; Nagase R; Horikawa S; Izawa K; Fukuyama T; Nakahara F; Oki T; Harada Y; Harada H; Aburatani H; Kitamura T
    Exp Hematol; 2015 Apr; 43(4):300-8.e1. PubMed ID: 25534203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia.
    Schmidt L; Heyes E; Grebien F
    Bioessays; 2020 Feb; 42(2):e1900178. PubMed ID: 31867767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia.
    Katzerke C; Madan V; Gerloff D; Bräuer-Hartmann D; Hartmann JU; Wurm AA; Müller-Tidow C; Schnittger S; Tenen DG; Niederwieser D; Behre G
    Blood; 2013 Oct; 122(14):2433-42. PubMed ID: 23974200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
    Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
    Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.
    Kirstetter P; Schuster MB; Bereshchenko O; Moore S; Dvinge H; Kurz E; Theilgaard-Mönch K; Månsson R; Pedersen TA; Pabst T; Schrock E; Porse BT; Jacobsen SE; Bertone P; Tenen DG; Nerlov C
    Cancer Cell; 2008 Apr; 13(4):299-310. PubMed ID: 18394553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene.
    Asou H; Gombart AF; Takeuchi S; Tanaka H; Tanioka M; Matsui H; Kimura A; Inaba T; Koeffler HP
    Genes Chromosomes Cancer; 2003 Feb; 36(2):167-74. PubMed ID: 12508245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBPα for ubiquitin-mediated proteasome degradation.
    Pal P; Lochab S; Kanaujiya JK; Kapoor I; Sanyal S; Behre G; Trivedi AK
    Cell Death Dis; 2013 Apr; 4(4):e590. PubMed ID: 23598402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation.
    Röhrs S; Scherr M; Romani J; Zaborski M; Drexler HG; Quentmeier H
    J Hematol Oncol; 2010 Apr; 3():15. PubMed ID: 20398252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
    Paz-Priel I; Cai DH; Wang D; Kowalski J; Blackford A; Liu H; Heckman CA; Gombart AF; Koeffler HP; Boxer LM; Friedman AD
    Mol Cancer Res; 2005 Oct; 3(10):585-96. PubMed ID: 16254192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
    Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
    Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C/EBPα in normal and malignant myelopoiesis.
    Friedman AD
    Int J Hematol; 2015 Apr; 101(4):330-41. PubMed ID: 25753223
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
    Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
    Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
    Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.